As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection.
Cindy KinM Kate BundorfPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2017)
The use of infliximab for ulcerative colitis has, as expected, increased since its approval, but so has the risk of surgery. Thus, the introduction of biologic therapy has not decreased the risk for surgery for this patient population.